A detailed history of Bank Of New York Mellon Corp transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 121,452 shares of ABEO stock, worth $691,061. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,452
Previous 121,453 0.0%
Holding current value
$691,061
Previous $515 Million 49.06%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.12 - $6.32 $4 - $6
-1 Reduced -0.0%
121,452 $768 Million
Q2 2024

Jul 25, 2024

BUY
$3.17 - $8.05 $7,715 - $19,593
2,434 Added 2.05%
121,453 $515 Million
Q1 2024

Apr 25, 2024

BUY
$4.07 - $8.68 $430,194 - $917,467
105,699 Added 793.54%
119,019 $863 Million
Q4 2023

Jan 29, 2024

BUY
$3.71 - $5.14 $1,432 - $1,984
386 Added 2.98%
13,320 $66.7 Million
Q2 2023

Aug 03, 2023

BUY
$2.76 - $5.27 $35,697 - $68,162
12,934 New
12,934 $52.1 Million

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.